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Malignant mesothelioma is a devastating disease that has been associated with loss of Neurofibromatosis
type 2 (NF2) and genetic lesions affecting RB and P53 pathways. We introduced similar lesions in the meso-
thelial lining of the thoracic cavity of mice. Mesothelioma developed at high incidence in Nf2;Ink4a/Arf and
Nf2;p53 conditional knockout mice with median survival times of approximately 30 and 20 weeks, respec-
tively. Murine mesothelioma closely mimicked human malignant mesothelioma. Conditional Nf2;Ink4a/Arf
mice showed increased pleural invasion compared to conditional Nf2;p53 mice. Interestingly, upon Ink4a
loss in the latter micemedian survival was significantly reduced and all tumors were highly invasive, suggest-
ing that Ink4a loss substantially contributes to the poor clinical outcome of malignant mesothelioma.
INTRODUCTION
Human malignant mesothelioma (MM) is an aggressive tumor
strongly associated with asbestos exposure (Knudson, 1995;
Liu et al., 2000; Murthy and Testa, 1999; Tiainen et al., 1989).
In view of the long latency period between exposure and disease
onset, the number of patients presenting with MM is expected to
rise in the coming decade and peak around 2015 (Murthy and
Testa, 1999; Hodgson et al., 2005). Pleural MM is the most prev-
alent form of humanMM,while peritoneal and pericardial MMare
less frequently seen. MM can be subdivided into three histolog-
ical types, i.e., epithelial, sarcomatoid, and mixed. Sarcomatoid
MMcannot always easily be discriminated from the various other
sarcomas that can arise in the thoracic cavity, e.g., leiomyosar-
comas, rhabdomyosarcomas, and osteosarcomas (Attanoos
et al., 2000; Cagle et al., 1989). In addition, it can also be difficult
to discriminate reactive fibroblast proliferations from sarcoma-
toid MM. In order to obtain a formal diagnosis of the different
subtypes, histological specimens are required to assess both
tumor morphology in combination with a set of (immunohisto-
chemical) markers (Cagle et al., 1989; Carter and Otis, 1988;
Khalidi et al., 2000; Ordonez and Tornos, 1997). Many markers
have been tested to date but no single marker can classify with
certainty a tumor as a MM (Ordonez, 1999). Although chemo-
therapy can lead to an improvement of overall and progres-
sion-free survival, this therapy is not curative and patients with
MMusually succumb from the diseasewithin a year after diagno-
sis (Knudson, 1995; Liu et al., 2000; Murthy and Testa, 1999;
Tiainen et al., 1989).
There is an urgent need for experimental models of MM that
can be used to not only study the onset and progression of the
disease, but also to serve as a model to select new combination
therapies and targeted agents. Different genetic lesions have
been found associated with human MM (Ascoli et al., 2001; Lee
and Testa, 1999; Sandberg and Bridge, 2001). Loss of the tumor
suppressor genes (TSG) INK4A and P14ARF, Neurofibromatosis
SIGNIFICANCE
Malignant mesothelioma is a devastating disease related to asbestos exposure. Although some improvements in survival
have been achieved, most patients die within 2 years after diagnosis. With the availability of new therapeutic agents with
high specificity, there is a clear need for mouse models that closely reproduce the disease as observed in man. Here we
describe the generation of such models. The models show a high incidence of mesothelioma with a relatively short latency.
Tumor induction is initiated by locotemporal somatic inactivation of tumor suppressor genes found defective in human
mesothelioma. Our mouse models should be suitable to further dissect the pathways critically important in mesothelioma
development and progression and serve as invaluable tools to test new intervention strategies.
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A Somatic Sporadic Murine Mesothelioma ModelFigure 1. Mesothelium-Specific Targeting of Cre Activity after
Intrathoric Administration of Adeno Viruses
(A) Mesothelium-specific recombination of the LacZ reporter transgene in
R26R reporter mice injected in thoracic cavity with 1 3 109 pfu of Adeno-
Cre virus indicated that mesothelial cells can be efficiently infected using
this protocol. Occasional staining was observed in the muscle cell layer
adjacent to the mesothelial cell lining. Virtually no staining was seen in
the lung parenchyma.
(B) Intrathoracic injections ofWT FVBmicewith Adeno-LacZ virus showed
a comparable b-galactosidase staining pattern, albeit stronger compared
to the b-galactosidase expression levels induced by Cre recombinase in
the R26R mice.type 2 gene (NF2), TRP53, and possiblyRB have been implicated
(Bianchi et al., 1995; Carbone et al., 1997; Cheng et al., 1994; De
Rienzo et al., 2001; Lechner et al., 1997; Mor et al., 1997; Papp
et al., 2001; Prins et al., 1998; Sekido et al., 1995). Expression
of SV40 T-antigen in pleural MM has been reported, suggesting
that inactivation of pocket protein and TP53 pathways may be
important in the development of MM (De Luca et al., 1997). How-
ever, SV40 T-antigen is only sporadically reported to be ex-
pressed in MM and its contribution to the development of MM
as an causative factor has been refuted (Hubner and Van Marck,
2002; Lopos-Rios et al., 2004). A number of groups have induced
MM inmice, rats, and hamsters through aerosolic administration
or injection of asbestos (Adamson et al., 1993; Craighead et al.,
1987; Fleury-Feith et al., 2003; Libbus et al., 1988; Marsella
et al., 1997; Sandhu et al., 2000) or through exposure to SV40
virus (Cicala et al., 1993; Rizzo et al., 2001). However, the MM
induced in rats by aerosolic exposure to asbestos fibers did not
show evidence for the loss of function of genes affected in human
MMor known nuclear targets of SV40 Tag (Adamson et al., 1993;
Craighead et al., 1987; Libbus et al., 1988; Marsella et al., 1997;
Sandhu et al., 2000).
We decided to determine whether mutations affecting the
same pathways found disrupted in human MM would also
cause MM in mice. Therefore, we generated mutant mice carry-
ing a range of single and compound lesions in the Nf2, p53, and
Ink4a pathways with the expectation that such mice might serve
as a suitable model for MM in man. In addition, this would allow
us to study other (un)known genes that might play an important
role in the initiation and progression of MM in both mouse and
man. Ink4a/Arf and Trp53 are TSG that are well known for their
role in cell-cycle regulation (Sharpless and Chin, 2003). The NF2
gene product, merlin or schwannomin (Nf2), belongs to the
band 4.1 family of cytoskeletal-associated ERM proteins (Bian-
chi et al., 1994; Claudio et al., 1994a, 1994b, 1995; Gusella
et al., 1999; Rouleau et al., 1993; Tikoo et al., 1994; Trofatter
et al., 1993) and is thought to be involved in the organization
of the actin cytoskeleton (Brault et al., 2001; Deguen et al.,
1998; den Bakker et al., 2000; Sainio et al., 1997; Takeshima
et al., 1994). It has been shown that reduced Nf2 expression
lowers cell adhesion and induces Schwann cell proliferation,
whereas enhanced expression of Nf2 leads to growth arrest
(Gutmann et al., 1998, 1999). Nf2 is a phosphoprotein and its
phosphorylation status can be modulated by numerous stimuli
in culture, i.e., growth factor availability and cell-cell contact
(Morrison et al., 2001; Shaw et al., 1998a, 1998b; Sherman
and Gutmann, 2001). More recently, data on Nf2 function
and its putative role in MM, i.e., Nf2’s involvement in Ras/Rac
262 Cancer Cell 13, 261–271, March 2008 ª2008 Elsevier Inc.signaling (Morrison et al., 2007) and signaling via PAK, which
is a key modulator of cell motility (Kissil et al., 2002; Xiao
et al., 2002), were published. Thus, Nf2 likely acts by linking
cell adhesion to cell proliferation (Morrison et al., 2001). Loss
of Nf2 in mice has been shown to induce a variety of tumors
with high metastatic potential (Giovannini et al., 1999, 2000;
McClatchey et al., 1998). In addition, MM often show inactiva-
tion of the INK4A;ARF locus. Therefore, we focused on the
inactivation of these loci. In view of the role of p16INK4A in the
RB pathway and p14ARF in the TRP53 pathway, we included
in the analysis compound mutants in which Rb and Trp53
were also affected.
To circumvent the pleiotropic effects or embryonic lethality
associated with Ink4a/Arf and Trp53 or Nf2 homozygous germ-
line gene disruption in mice (Giovannini et al., 2000; McClatchey
et al., 1997; Serrano et al., 1996), we employed conditional
knockout (CKO) mice for Nf2, Trp53, Rb, and Ink4a/Arf TSG us-
ing the Cre-LoxP system (Akagi et al., 1997; Jonkers and Berns,
2002; Jonkers et al., 2001; Loonstra et al., 2001; Meuwissen
et al., 2001). We sought to limit the inactivation of the conditional
TSG through locotemporal introduction of adenoviruses encod-
ing the site-specific recombinase Cre, i.e., Adeno-Cre (Akagi
et al., 1997; Anton and Graham, 1995; Shibata et al., 1997). We
and others have shown that replication defective adenoviruses
will efficiently infect most cell types in vivo and elicit efficient
gene recombination (Jackson et al., 2001; Meuwissen et al.,
2001; Shibata et al., 1997).
Here, we describe the generation of a mouse model for
sporadic MM utilizing direct injection of Adeno-Cre virus in the
pleural cavity of adult mice carrying conditional TSG knockout
alleles for Nf2, p53, Rb, and Ink4a/Arf.
RESULTS
Mesothelium-Specific Recombination
in the Thoracic Cavity
Injection of Adeno-Cre into the thoracic cavity of Rosa26 LacZ
(R26R) reporter mice (Soriano, 1999) resulted in b-galactosidase
expression of the mesothelial linings (Figure 1A), indicating that
mesothelial cells can be efficiently infected. Occasional staining
was observed in themuscle cell layer underneath themesothelial
cell lining. Virtually no staining was seen in the lung parenchyma.
Intrathoracic injections of wild-type (WT) FVB mice with Adeno-
LacZ virus (Figure 1B) showed a comparable b-galactosidase
staining pattern. A small amount of adenovirus might end up
in the circulation and can give rise to tumors elsewhere (see
below).
Cancer Cell
A Somatic Sporadic Murine Mesothelioma ModelFigure 2. Overview of the MM Tumor Spectrum Induced by
Adeno-Cre Virus in the Different Genetic Backgrounds
The epitheloid, sarcomatoid, and mixed tumors were found with variable
frequency, depending on the different genetic backgrounds. The invasive
tumors in theNf2F;Ink4a/ArfFmice were almost all of the sarcomatoid type,
although nodular tumors were also observed near the invasive tumors (A,
B, andC). Examples are shown for vertebrae invasion (A), lung invasion (B),
and invasion of the diaphragm (C). In the Nf2F;p53F mice, tumors ranged
from nodular, noninvasive visceral to nodular, locally invasive visceral
and invasive parietal growth patterns. In the sarcomatoid tumors invading
muscle layers, a typical ‘‘signet-cell’’-like picture was observed, especially
when cells invaded the esophagous. Some tumors grew as large nodular
tumors on the chest wall, whereas others grew at multiple sites along the
lungmesothelial cell layer (D, E, and F). Examples are shown for a nodular,
noninvasive tumor (D), a vertebrae-invading tumor (E), and a local invasive
tumor invading themuscularis and submucosa of the esophagous (F). The
addition of the conventional Ink4a* knockout to Nf2F;p53F mice created
the spectrum of nodular, invasive, and aggressive tumor growth at both
the lung mesothelial cell layer as well as in the chest wall and diaphragm
(G, H, I, J, K, and L). Examples are shown for a tumor growing along the
diaphragm (G), a tumor growing inside the atrium of the heart (H and I),
tumors invading either the lungs or the thoracic wall (J and K), and thoracic
wall invasion (L). tw, thoracic wall; d, diaphragm; o, esophagus; l, lung;
h, heart; v, vertebra. Bars for different magnifications are shown as burn
in marks (Axiocam, Color-CCD camera).Locotemporal Inactivation of Nf2 Together with Either
Ink4a/Arf or p53 Gives Rise to a Variety of Tumors
We induced mesothelial-specific loss of Nf2, Ink4a/Arf, and p53
TSG by locotemporal expression of Cre recombinase upon intra-
thoracic Adeno-Cre injection in mice. We used homozygous
CKO for Nf2, Ink4a/Arf, and p53, and homozygous compound
CKO Nf2;Ink4a/Arf and Nf2;p53 carrying either an active or inac-
tive Ink4a allele (Ink4a*) (Krimpenfort et al., 2001) and matched
heterozygous CKO mice. The tumors that arose in our mouse
cohorts mainly comprised thoracic tumors (including MM, rhab-
domyosarcomas, and schwannomas), lymphomas, or leukemia
and leiomyomas of the uterus wall. Hepatomegaly was also
frequently observed (see Table 1). A portion of the mice died of
age-related or nonspecific causes, e.g., papillary lung tumor
development or heart failure.
InNf2F/F;Ink4a/Arf F/F (n = 57),Nf2F/F;p53F/F (n = 55), andNf2F/F;
p53F/F;Ink4a*/* (n = 51) mice, thoracic tumors were identified by
H&E staining in 80%–100% of the mice (Figure 2). Nf2F/F;p53F/F
mice developed either nonaggressive epitheloid or mixed tu-
mors with confined invasion of the visceral pleura or (sarcoma-
toid) tumors with strong invasion of both visceral and parietal
pleura accompanied by pleural effusions, whereasNf2F/F;p53F/F;
Ink4a*/* as well as Nf2F/F;Ink4a/Arf F/F mice almost exclusively
developed highly invasive tumors.
We observed similar tumors in the heterozygous groups, i.e.,
Nf2F/WT;Ink4a/ArfF/F (n = 41) mice, Nf2F/F;Ink4a/Arf F/WT (n = 52)
mice, Nf2F/WT;p53F/F (n = 34) mice, and Nf2F/F;p53F/WT (n = 20)
mice as found in the homozygous group, except that the latency
period was longer (Table 1). In Nf2F/F;p53F/F;Ink4a*/WT mice (n =
16), we observed aggressive thoracic tumor growth. The parietal
pleura, i.e., chest wall and diaphragm often showed invasion
with concomitant pleural effusions.
In 30 Nf2F/F mice and 13 p53F/F;Ink4a*/* mice, we observed
5 and 2 MM-like thoracic tumors, respectively, whereas
these were not observed in 19 p53F/F mice and 17 Ink4a/ArfF/F
mice.Hepatomegaly either due to oval cell hyperplasia, cholangio-
carcinomas and/or hepatomas, and leiomyomas of the uterus
were observed throughout all genotypes carrying Nf2F/F alleles
except in Nf2F/F;p53F/F;Ink4a*/* and Nf2F/F;p53F/F;Ink4a*/WT
mice that succumbed to MM before the onset of hepatomegaly
or leiomyoma (Table 1). A few thymic lymphomas were observed
in Nf2F/F;p53F/F and Nf2F/F;p53F/WT, whereas monocytic myeloid
leukemias (MML) were found in four Nf2F/F;Ink4a/ArfF/F, eight
Nf2F/F;Ink4a/ArfF/WT and 22Nf2F/WT;Ink4a/ArfF/Fmice (see Table
1). p53F/Fmice primarily developed malignant lymphomas, oste-
osarcomas, or leiomyosarcomas, whereas Ink4a/Arf F/Fmice de-
veloped mostly MML as well as leiomyosarcomas. The Ink4a*/*;
p53F/F mice primarily developed malignant lymphomas from
spleen with spreading to liver and lungs. The occurrence of other
tumors is due to infection of other cell types that are known to
be particularly susceptible to tumor development upon deletion
of these TSG. Spreading of a small amount of Adeno-Cre then
suffices to induce these tumors, especially in genotypes in which
MM development is delayed.
Immunohistochemistry of Epitheloid, Sarcomatoid, and
Mixed Murine MM in the Different Compound Mutants
Immunohistochemistry (IHC) of the thoracic tumors in Nf2;Ink4a/
Arf, Nf2;p53, and Nf2;p53;Ink4a* cohorts allowed us to discrim-
inate between MM, rhabdomyosarcomas, and schwannomas.
MM stained positive for pankeratin, keratin8, vimentin, and mes-
othelin and negative for Myf-4 (Figure 3). Some invasive tumors
showed partly positive staining for smooth muscle actin due to
local angiogenesis and S-100 due to invasion of tumor cells
into peripheral nerve sheets (data not shown). In a few cases,
a MM and a rhabdomyosarcoma were found in the same animal
as reflected by keratin8 and Myf4 staining pattern (Figure 3).
Alcian blue staining was performed with and without hyaluroni-
dase treatment to identify MM in those cases where keratin 8,
vimentin, and mesothelin stainings were inconclusive.Cancer Cell 13, 261–271, March 2008 ª2008 Elsevier Inc. 263
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A Somatic Sporadic Murine Mesothelioma ModelTable 1. Locotemporal Inactivation of Nf2 Together with Ink4a/Arf, p53, or Both p53 and Ink4a Gives Rise to a Variety of Tumors
Nf2F;p53F Nf2F;Ink4a/ArfF Nf2F;p53F;Ink4a*
Genotype
het;hom
(n = 34)
hom;hom
(n = 55)
hom;het
(n = 20)
het;hom
(n = 41)
hom;hom
(n = 57)
hom;het
(n = 52)
hom;hom;het
(n = 16)
hom;hom;hom
(n = 51)
Tumor (site)
Mice with thoracic tumors 21 (61.8) 47 (85.5) 8 (40.0) 14 (34.1) 47 (82.5) 18 (34.6) 15 (93.8%) 51 (100%)
MM, epithelial 5 7 3 4 1 4 0 0
MM, sarcomatoid 5 21 2 3 31 5 6 36
MM, mixed 10 17 0 7 13 9 9 11
Rhabdomyosarcoma 0 2 0 0 3 0 1 4
Schwannoma 1 1 3 0 1 0 0 1
Lymphoma, MML leukemia 3 (8.8) 4 (7.3) 5 (25.0) 22 (53.7) 4 (7.0) 8 (15.4) 0 0
Uterus wall tumor (leiomyoma) 3 (8.8) 4 (7.3) 5 (25.0) 7 (17.1) 2 (3.5) 8 (15.4) 0 0
Hepatomegaly 0 2 (3.6) 1 (4.0) 0 24 (42.1) 12 (23.1) 0 0
Aspecific tumor 7 (20.6) 6 (10.9) 2 (8.0) 10 (24.4) 2 (3.5) 10 (19.2) 1 (6.2) 0
Locotemporal inactivation ofNf2 together with either Ink4a/Arf, p53, or both p53 and Ink4a gives rise to a variety of tumors. Somemicewere diagnosed
with both MM and another tumor, e.g., rhabdomyosarcoma or schwannoma. The tumors in Nf2F;Ink4a/ArfF and Nf2F;p53F are arranged by genotype
in three different columns, het;hom, hom;hom, and hom;het, respectively. For Nf2F;p53F;Ink4a*, we only show the hom;hom;het and hom;hom;hom
combinations. Aspecific tumors are tumors that have not been induced by adenoCre virus, e.g., papillary lung tumors. Hom, homozygous; het,
heterozygous.Subdivision of theMM into (1) epitheloid nodular tumors invad-
ing local visceral pleura, (2) sarcomatoid tumors invading both
the visceral and parietal pleura, and (3) mixed epitheloid and
sarcomatoid tumors invading either the visceral or parietal pleura
was performed for all cohorts. Epithelial MMwas found inNf2F/F;
p53F/F and Nf2F/F;Ink4a/Arf F/F mice, but not in Nf2F/F;p53F/F;
Ink4a*/* mice. Sarcomatoid MM and mixed MM were found in
Nf2F/F;p53F/F, Nf2F/F;Ink4a/ArfF/F, and Nf2F/F;p53F/F;Ink4a*/*
mice (Table 1).
Latency of MM Development
MM primarily arose in Nf2;p53 or Nf2;Ink4a/Arf CKO mice. The
Kaplan Meier survival curves of MM in Nf2;Ink4a/Arf, Nf2;p53,
and Nf2;p53;Ink4a* CKO mice are shown in Figure 4. MM in
Nf2;Ink4a/Arf CKO mice showed a shorter latency period in
comparison to both heterozygous groups (Figure 4A). Median
survival time ranged from 220 days in Nf2;Ink4a/Arf CKO mice
to 410 and 495 days in mice carrying one WT Nf2 or Ink4a/Arf
allele, respectively. MM development in homozygous Nf2;p53
conditional mutants was accelerated compared to matched
heterozygotes (Figure 4B). Median survival time ranged from
135 days in Nf2;p53 homozygous mice to 215 and 605 days in
mice carrying one WT Nf2 or p53 allele, respectively.
These observations indicate that loss of Nf2, p53, or Ink4a/Arf
each substantially contribute to development of MM. By com-
paring the full CKO mice in Figures 4A and 4B, a clear shift is
seen in tumor latency, i.e., median survival time of 220 days
(Nf2;Ink4a/Arf) compared to 135 days (Nf2;p53).
Figure 3. IHC Analysis of Murine Thoracic Sarcomatoid Tumors
The sarcomatoid tumors that stained positive for pankeratin (A), keratin 8
(B and C), and mesothelin (D) and negative for Myf-4 (E) were designated
asMM. The commonly used combined expression of keratin (left, DAB [di-
aminobenzidine]) and vimentin (right, AEC [3-amino-9-ethylcarbazole]) by
mesothelial cells is also shown (F). Other tumor types are a few rhabdomy-
sarcomas ([G], HE-staining; [H], Myf4-positive) or leiomysarcoma ([I],
SMA-positive). Bars for different magnifications are shown as burn in
marks (Axiocam, Color-CCD camera).264 Cancer Cell 13, 261–271, March 2008 ª2008 Elsevier Inc.
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A Somatic Sporadic Murine Mesothelioma ModelFigure 4. The Latency Curves for Tumors Arising after
Intrathoracic Adeno-Cre Injections in Conditional
Nf2;Ink4a/Arf, Nf2;p53, and Nf2;p53;Ink4a* Mice
(A) Kaplan Meier analysis for survival in days by genotype is
shown in the upper left panel for the Nf2;Ink4a/Arf combina-
tions. MM latency in Nf2;Ink4a/Arf homozygous CKO mice
clearly shifted to the left in comparison with either heterozy-
gous control group. For the Nf2;Ink4a/Arf mice, median sur-
vival time ranged from 220 days in Nf2;Ink4a/Arf homozygous
CKOmice compared to 410 and 495 days in mice carrying one
WTNf2 or Ink4a/Arf allele, respectively.Nf2;Ink4a/Arf homozy-
gous CKO significantly differed from both control groups (log
rank test, p < 0.00001) as well as both heterozygous groups
differed from each other (log rank test, p < 0.035).
(B) Kaplan Meier analysis for survival in days by genotype are
shown in the upper right panel for the Nf2;p53 combinations.
MM latency in Nf2;p53 homozygous CKO mice also clearly
shifted to the left in comparison to both heterozygous control
groups. For the Nf2;p53 mice, median survival time was 135
days in Nf2;p53 homozygous CKO mice compared to 215
and 605 days in mice carrying one WT Nf2 or p53 allele, re-
spectively. Nf2;p53 homozygous CKO mice significantly dif-
fered from both control groups (log rank test, p < 0.00001)
as well as both heterozygous groups differed from each other
(log rank test, p < 0.0025).
(C) Inclusion of the Ink4a* knockout allele (Krimpenfort et al.,
2001) in Nf2;p53 CKO mice shifted the tumor latency curve
for these mice strikingly to the left. Red, purple, and green colors mark sarcomatoid tumors growing invasive in both parietal and visceral pleura, mixed tumors
locally invasive in visceral pleura, and nodular tumors locally invasive in visceral pleura, respectively. Note that most tumors in the left curve are invading both
parietal and visceral pleura.
In Figure 4C,median survival timewas 80 days inNf2F/F;p53F/F;Ink4a*/* mice compared to 135 and 220 days inNf2;p53 andNf2;Ink4a/ArfCKOmice, respectively.
All three groups differed significantly (log rank test, p < 0.00001).Interestingly, we observed a marked difference in the aggres-
siveness of the tumors between genotypes. Whereas the most
aggressive phenotype was observed in Nf2;Ink4a/Arf tumors
(70%), a substantial variation in malignancy, i.e., in invasive
behavior, was seen in Nf2;p53 tumors. This led to the question
whether loss of function of Ink4a might be responsible for the
increased malignancy of Nf2;Ink4a/Arf tumors.
To answer this question, the Ink4a* allele, which is functional
for Arf, was crossed into Nf2F/F;p53F/F mice. In Nf2F/F;p53F/F;
Ink4a*/* mice, the tumor latency was markedly reduced as
compared to Nf2F/F;p53F/F mice (Figure 4C). Median survival
time was 80 days in Nf2F/F;p53F/F;Ink4a*/* mice compared to
135 and 220 days in Nf2F/F;p53F/F and Nf2F/F;Ink4a/ArfF/F mice,
respectively. Note that most of the tumors induced in Nf2F/F;
p53F/F;Ink4a*/* mice (75%) are highly malignant as observed by
both parietal and (local) visceral pleural invasion, whereas only
half of the tumors induced in Nf2F/F;p53F/F mice shows invasion
of both visceral and parietal pleura and one-third shows local
invasion of the visceral pleura only. Ink4a loss, thus, seems to
confer a more aggressive behavior to murine MM cells. This is
accompanied by pleural effusions, invasive tumor growth into
the parietal pleura of the chest wall, the esophagus or intestine
causing gastro-intestinal obstruction, and subsequent weight
loss leading to a shorter latency period.
IHC for p16Ink4a Expression in Murine MM
In order to investigate whether p16Ink4a expression in murineMM
is directly correlated with tumor malignancy, we performed IHC
for p16Ink4a in tumors induced inNf2F/F;p53F/Fmicewith andwith-
out invasive/aggressive growth features. Most of the nodular andlocal visceral pleura invading tumors showed strong nuclear
staining for p16Ink4a (Figure 5A). Some of the invasive counter-
parts in theparietal pleuraof these tumors showedeither apatchy
stainingpattern focusedat theedgesof tumor invasionorastrong
reduction in nuclear staining (Figure 5B). Other invasive parietal
pleural tumors stained completely negative for p16Ink4a, and
a few showedstrong nuclear staining in themore invasive parietal
part of the tumor. As expected, tumors induced in Nf2F/F;Ink4a/
Arf F/F mice did not stain for p16Ink4a, validating the specificity of
our antibody (Figure 5C). In Ink4a*/WT tumors, we did observe
strongnuclear staining in thenodular tumors (Figure 5D), presum-
ably caused by the remainingWT Ink4a allele, whereas in someof
the invasive counterparts in the parietal pleura, the p16Ink4a pro-
tein staining was reduced. In Ink4a*/* homozygous tumors, no
p16Ink4a expression was observed (Figure 5E).
We also analyzed the methylation status of the Ink4a allele
in MM induced in Nf2F/F;p53F/F and Nf2F/F;p53F/F;Ink4a*/WT
tumors to verify whether a correlation could be found between
methylation and malignancy of the Nf2;p53 tumors. To exclude
contamination with normal cells, we used primary cell cultures
of mesothelial tumors and could show Ink4a promotor methyla-
tion in only 1 out of 9 tumors in Nf2F/F;p53F/F mice (data not
shown), indicating that epigenetic inactivation of Ink4a is unlikely
to contribute significantly to MM development in tumors of
Nf2F/F;p53F/F mice, although loss of Ink4a accelerates tumor
onset and augments malignancy. In none of the Nf2F/F;p53F/F;
Ink4a*/WT tumors (14 tested) were we able to show methylation
of the Ink4aWT allele, which is in agreement with findings of
Sharpless et al. who could also not detect methylation of the
WT allele in heterozygous Ink4amutants (Sharpless et al., 2002).Cancer Cell 13, 261–271, March 2008 ª2008 Elsevier Inc. 265
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(A) IHC for p16Ink4a in Nf2;p53 tumors with and without invasive/aggres-
sive growth features. Most of the nodular and local visceral pleura invad-
ing tumors showed strong nuclear staining for p16Ink4a.
(B) Some of the invasive counterparts in the parietal pleura of these
NF2;p53 tumors showed either a patchy staining pattern of the tumors
or a strong reduction of nuclear staining with slightly increased staining
at the edges of the tumors.
(C) Other invasive parietal pleural tumors stained completely negative for
p16Ink4a and a few showed strong nuclear staining in the more invasive
parietal part of the tumor. Nf2;Ink4a/Arf tumor cells stained completely
negative for p16Ink4a.
(D) In Ink4a* heterozygous tumors we did observe strong nuclear staining
of WT p16Ink4a in the nodular tumors.
(E and F) In Ink4a* homozygous tumors we observed no staining of the
mutant protein (E) when compared to PBS control (F). Bars for differ-
ent magnifications are shown as burn in marks (Axiocam, Color-CCD
camera).Assessment of Biallellic Recombination or Loss
of Heterozygosity of Nf2, p53, or Ink4a in Murine
MM Development
MM arising in mice carrying combinations of conditional Nf2,
Ink4a/Arf, and p53 alleles were analyzed for Cre-mediated
recombination and loss of heterozygosity (LOH) by Southern
blotting.Nf2, p53, and Ink4a/Arf status were determined in tissue
samples from all above mentioned groups. Most tumor samples
in the Nf2;p53 and Nf2;p53;Ink4a* cohorts showed Adeno-Cre-
induced partial deletion of theNf2 exon 2 (Figure 6A). We ascribe
this apparent partial recombination to contamination with sur-
rounding WT cells (see below). This contamination was highest
in the more invasive tumors. A similar observation was made
Figure 6. Biallelic Recombination and LOHAnalysis forNf2, p53, and
Ink4a in Murine MM Samples
Nf2 and p53 status were determined in tumor samples from Nf2;p53,
Nf2;p53;Ink4a*, andNf2;Ink4a/Arfmice (A andB). Most tumor samples (PT) de-
rived fromNf2;p53, andNf2;p53;Ink4a* CKOmice showed Adeno-Cre induced
(partial) deletion of theNf2 exon 2 (A) as opposed to liver controls (L). Presence
of the unrecombined allele in the analysis is likely due to contamination with
DNA extracted from stromal cells. This contamination was highest in the
more invasive tumors. The picture for Adeno-Cre-induced recombination of
p53 exons 2–10 is comparable in both cohorts (B). Tissue-culture-propagated
cells (C) derived from either pleural effusions or primary tumor showed com-
plete recombination of conditional Nf2 or p53 alleles and LOH of the WT Nf2
and p53 allele in the case of heterozygotes.266 Cancer Cell 13, 261–271, March 2008 ª2008 Elsevier Inc.forCre-induced recombination ofp53 in both cohorts (Figure 6B).
Tissue culture-propagated cells derived from either pleural
effusions or primary tumors showed complete recombination
of conditional Nf2 or p53 alleles and LOH of the WT Nf2 allele
in the case of heterozygotes. Likewise, the tumors in the Nf2F/F;
Ink4a/Arf F/F cohort exhibited partial Ink4a/Arf and Nf2 recombi-
nation. The levels of recombination of both alleles was compara-
ble (data not shown). Tissue culture propagated and soft-agar
cloned cells derived from either pleural effusions or primary tu-
mor showed complete recombination of both conditional alleles
and LOH of the WT Nf2 allele in case of a Nf2F/WT germline
configuration. The sometimes limited recombination of Nf2 and
Ink4a/Arf in primary tumors is likely caused by stromal contami-
nation in view of the similar extent of recombination of the
different TSG and the subsequently complete recombination
observed after in vitro propagation of the tumors (data not
shown). In a few Ink4a*/WT samples, we were not able to detect
the remaining WT Ink4a allele in Nf2F/F;p53F/F;Ink4a*/WT tumors
(data not shown), which may indicate loss of the WT allele.
In Vivo Bioluminescent Imaging of Spontaneous
Murine MM Development
After crossing in a luciferase reporter (LucR) (Lyons et al., 2003),
we were able to follow the development of MM in both Nf2F/F;
p53F/F and Nf2F/F;p53F/F;Ink4a*/* mice noninvasively. An exam-
ple of a bioluminescent primary tumor is shown in Figure 7A at
9 weeks after IT injection of Adeno-Cre virus. Through soft-
agar cloning of primary tumor cell suspensions, we were able
to generate clonal cell lines from all three genetic backgrounds
with or without this LucR (see Supplemental Data available
online, Table S1). The LucR+ clonal cell line derived from the pri-
mary tumor shown in Figure 7A gave rise to LucR+ tumors upon
orthotopic grafting into syngeneic hosts (Figure 7B). Histological
examination of H&E-stained sections of both primary (Figure 7C)
and orthotopic tumor (Figure 7D) showed very similar growth and
invasive characteristics.
DISCUSSION
We describe here the development of a conditional mouse
model for human MM. To this end, we induced mesothelial-spe-
cific loss of Nf2, Ink4a/Arf, and p53 TSG by locotemporal
Cancer Cell
A Somatic Sporadic Murine Mesothelioma ModelFigure 7. Noninvasive Follow-Up of Spontaneous Murine MM
Development
(A) After crossing in a luciferase reporter allele (LucR), we followedMMde-
velopment in both Nf2F/F;p53F/F and Nf2F/F;p53F/F;Ink4a*/* mice noninva-
sively. An example of a bioluminescent primary tumor is shown at 9 weeks
after IT injection of Adeno-Cre virus. (B) A LucR+ clonal cell line derived
from the primary tumor shown in (A) gave LcR+ tumors upon orthotopic
grafting into syngeneic hosts. Upon histological examination on H&E-
stained sections, both primary (C) and orthotopic tumor (D) showed the
same invasive growth characteristics (invasive growth into thoracic wall,
tw; vertebrae, v). Bars for different magnifications are shown as burn in
marks (Axiocam, Color-CCD camera).expression of Cre recombinase via intrathoracic Adeno-Cre in-
jection in mice. We used homozygously floxed conditional single
(Nf2, Ink4a/Arf, and p53) and compound Nf2;Ink4a/Arf, Nf2;p53,
and Nf2;p53;Ink4a*/* alleles and heterozygously floxed litter-
mates. Although a range of different tumors were found in the
conditional mutants due to either infection of tissues other than
the mesothelial lining or to other tumor types developing intra-
thoracically, the vast majority of the mice developed MM. The
most common sites for MM development were the visceral
pleura of lungs and heart. The sites for secondary or locally me-
tastasized MM development were parietal pleura of diaphragm
and thoracic chest wall.
Comparison of MM in Man and Mouse
and the Role of Asbestos
Our analysis was driven by the lack of good mouse models that
have hampered a thorough understanding of the molecular
mechanisms underlying MM. This has allowed us to define the
TSG that, upon loss of function, give rise to sporadic MM and
to compare the histopathological phenotypes with asbestos-
inducedMM inmouse andman. Little is known about the (histo)-
pathology of murine MM induced by SV40 T antigen or asbestos
(Craighead et al., 1987; Topov and Kolev, 1987). Recently, it has
been shown that intraperitoneal asbestos exposure of Nf2WT/
mice leads to peritoneal MM. These tumors exhibit features of
human MM and arise with a median latency of 300 days (Alto-
mare et al., 2005). Since a diversity of tumors has been found
in Nf2WT/ mice either with or without metastasizing capacities
(Giovannini et al., 1999, 2000; McClatchey et al., 1998), it was
necessary to clearly distinguish the murine MM from other tho-
racic sarcomatoid tumors. To make this distinction, we used
a panel of histological markers that included panKeratin, N-Cad-
herin, mesothelin, calretinin, vimentin, MCM-7, SMA, S-100,
TTF-1, and Myf-4 supplemented with PTAH and Alcian Blue
staining.
The murine MM latency curves indicated that loss of Nf2, p53,
and Ink4a/Arf each substantially contribute to MM development.
Inclusion of the conventional Ink4a*/* (Krimpenfort et al., 2001)
knockout allele in the Nf2F/F;p53F/F mice significantly reduced
the latency period. MM in both Nf2F/F;p53F/F;Ink4a*/* as well as
in Nf2F/F;p53F/F;Ink4a*/WT mice presented as multiple tumors of
epithelial, mixed, and sarcomatoid phenotype. Moreover, all
these fast occurring epitheloid and sarcomatoid MMwere highlyinvasive in both parietal and visceral pleura, this in contrast to
the tumors induced in Nf2F/F;p53F/F mice. We conclude that
Ink4a loss confers a more aggressive invasive phenotype to
murine MM.
Whereas in humans a preponderance of the epithelial type of
MM opposed to sarcomatoid and mixed type is found, the
epitheloid tumors do tend to become invasive in the final stages
of the disease. In our mice models, pure epithelial MM were
found in Nf2F/F;p53F/F and Nf2F/F;Ink4a/Arf F/F mice, but not in
Nf2F/F;p53F/F;Ink4a*/* mice. Sarcomatoid and mixed MM were
found in all three experimental groups. The mixed tumors in
Nf2F/F;p53F/F;Ink4a*/* mice exhibited features of epitheloid MM
with large cytoplasmic vacuolization or ‘‘signet cell differentia-
tion,’’ which is often observed in epithelial-type MM as well as
sarcomatoid MM traversing parietal pleura, i.e., thoracic wall
and diaphragm. Likely, the predominant epithelial MM type
seen in man opposed to mice may occur as a result of spe-
cies-specific differences or relate to the route of induction, i.e.,
the long latency for MM development as a result of asbestos
exposure in humans opposed to somatically induced (homozy-
gous) mutations in specific genetic loci in mice.
The Cre-induced biallelic loss ofNf2 in themesothelial lining of
Nf2F/F;p53F/F and Nf2F/F;p53F/F;Ink4a*/* CKO mice results in a
shorter latency than seen inNf2F/F;Ink4a/Arf F/FCKOmice, which
exhibits a comparable latency as asbestos-induced MM in mice
heterozygous forNf2. In two separate studies, intraperitoneal as-
bestos experiments with mice heterozygous for Nf2 resulted in
MMwithin 6months (Fleury-Feith et al., 2003) and 10months (Al-
tomare et al., 2005) after exposure. In both cases, MM formation
was associated with loss of the WT NF2 allele, and in the latter,
most interestingly, tumors had either lost the Ink4a/Arf locus or
the p53 locus. These results imply that loss of the WT Nf2 allele
may occur rapidly in conjunction with asbestos exposure and
that asbestos may have multiple intracellular genotoxic effects,
e.g., loss of Ink4a/Arf locus.
How then does asbestos induce MM? Since loss of p16INK4A
and NF2 function is frequently observed in human MM, it seems
likely that the mechanical and oxidative damage inflicted by
asbestos fibers can bring about multiple genetic lesions of which
loss of NF2 and the INK4A/ARF locus appear critical. The rele-
vance of NF2 is further supported by the supposedly enhanced
susceptibility of an NF2 patient to asbestos-induced mesotheli-
oma (Baser et al., 2002).Cancer Cell 13, 261–271, March 2008 ª2008 Elsevier Inc. 267
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Examination of Cre-mediated gene inactivation in tumors
showed variable deletion frequencies of Nf2, Ink4a/Arf, and
p53 alleles. In contrast, complete Cre-mediated gene inactiva-
tion was found upon ex vivo propagation of MM, suggesting
incomplete deletion found in whole tumor DNA was a result of
contamination with WT cells. This stromal compartment was
lost during subcloning to derive cell lines. When tumors were
induced in mice carrying one WT allele of either Nf2, Ink4a/Arf,
or p53, we observed almost invariably loss of the WT allele by
LOH. Even in tumors from Nf2F/F;p53F/F;Ink4a*/WT mice, we
observed in a number of instances loss of the Ink4a WT allele.
Therefore, LOH analyses of tumors that arose in various mutant
backgrounds unequivocally demonstrate the importance of loss
of Nf2, Ink4a, and p53 for MM formation in line with the notion
that this model mimics human MM well (Carbone et al., 1997;
Lechner et al., 1997; Murthy and Testa, 1999; Papp et al.,
2001; Bianchi et al., 1995; Sekido et al., 1995).
Fleury-Feith et al. showed that hemizygosity of Nf2 was asso-
ciated with increased susceptibility to asbestos-induced perito-
neal tumors, including LOH of Nf2 in several asbestos-induced
neoplastic ascitic fluids (Fleury-Feith et al., 2003). Likewise,
Altomare et al., showed in asbestos-exposed Nf2 (+/) mice
markedly accelerated MM tumor formation compared with as-
bestos-treated WT littermates. Loss of the WT Nf2 allele, leading
to biallelic inactivation, was observed in all asbestos-induced
MM from Nf2 (+/) mice and in half of the asbestos-exposed
WT mice (Altomare et al., 2005). Our conditional model shows
that concomitant loss of Ink4a/Arf or p53 on top of Nf2 is suffi-
cient to induce MM development without requiring asbestos
exposure, suggesting that mutations in Nf2, in combination
with loss of Ink4a/Arf or p53, are critical events in MM develop-
ment, in accordance with the lesions observed in these genes
in human MM.
Our observations in mice closely mimic the observations in
man in which loss of these same genes is frequently seen (Bian-
chi et al., 1995; Sekido et al., 1995). Loss of the NF2 and INK4A/
ARF loci are often associated with asbestos-induced MM. Com-
paring theNf2F/F;Ink4a/ArfF/F cohort to the Nf2F/F;p53F/F;Ink4a*/*
cohort allows us to define differences in the consequences of Arf
and p53 loss on murine MM development in a Nf2;Ink4a null
background. The reasons to include a p53 conditional allele
were several fold. It allows us to define differences between
p53 and Arf loss in a well-defined tumor model. This is an issue
of general relevance. Second, from different systems we know
that p53 loss results in an increased genomic instability. In
a way, this would make it easier to score for chromosomal
changes that otherwise are induced by asbestos. Third, it
permits us to evaluate whether p53 deficiency wouldmake these
tumors more refractory to DNA-damaging drugs than tumors
with Arf inactivation. If this were the case one might exploit this
feature therapeutically by exploring DNA damage as part of the
intervention strategy in the mostly p53-proficient MM.
Although SV40 T-Ag alone can induce MM in rodents (Adam-
son et al., 1993; De Luca et al., 1997; Marsella et al., 1997) it
remains questionable to what extent this alternative route of
MM induction represents a useful model for MM inman. A recent
publication did show the synergistic effects of mesothelin-driven268 Cancer Cell 13, 261–271, March 2008 ª2008 Elsevier Inc.SV40-T-Ag expression and asbestos exposure (Robinson et al.,
2006). The fact that Ink4a loss clearly contributes to MM devel-
opment, whereas an effect on tumorigenicity was not seen for
Rb in combination with Nf2 alone (see Supplemental Data, Table
S2), suggests that (also) inactivation of other pocket proteins
might be required for MM development, although we did not an-
alyze the effect of Rb loss in Nf2F/F;p53F/F CKOmice. The strong
effect of Nf2 loss on MM development may relate to the unique
nature of the mesothelial cell layer in which control of cell prolif-
eration and differentiation relies on cell surface signaling cues in
which Nf2 plays a critical role. In this respect, it will be of interest
to study whether loss or overexpression of other components
that interact with NF2 or act downstream of Nf2 can modulate
MM development. Recent work has shown that reexpression
of Nf2 both inhibits cell proliferation via repression of cyclin D1
(Xiao et al., 2005) and impairs cell spreading and invasiveness
by attenuating FAK activity (Poulikakos et al., 2006). It will be
of interest to determine cyclin D1 levels and the invasive pheno-
type of our MM cell lines after reexpression of functional Nf2.
An Unexpected Role of Ink4a Loss
on Murine MM Development
Most of the nodular tumors stained strongly positive for p16Ink4a
in the nucleus. In some Ink4aWT/WT and Ink4a*/WT tumors,
p16Ink4a expression was lost when the cells invaded the parietal
pleura. However, we also observed invading tumors that still
exhibited a strong patchy nuclear staining. Therefore, although
p16Ink4a loss of function is frequently associated with increased
malignancy, the correlation is not seen in all cases, and no con-
sistent change in p16Ink4a expression is observed at the invading
front. While loss of p16Ink4a seems to facilitate invasive growth,
there are apparent other routes to invasiveness. Our observa-
tions in mice carrying either the Ink4a/ArfCKO or the Ink4a* allele
support the notion that loss of Ink4a is one of the factors that may
contribute to the more invasive behavior of murine MM cells.
Similar observations were made in the malignant progression
caused by Ink4a/Arf loss in a model of metastatic pancreatic
adenocarcinoma (Aguirre et al., 2003).
In conclusion, we have established a murine model for human
MM. Tumors develop after a short latency period in the vast
majority of themice and can be followed noninvasively using bio-
luminescence imaging. This will serve as a starting point to iden-
tify additional recurrent genetic changes and distinct expression
characteristics that might define new pathways that are critical
for MM development and allow us to design better intervention
strategies for this devastating cancer. We have derived a series
of cell lines that reproduce the disease upon orthotopic intratho-
racic grafting. These may facilitate these studies.
EXPERIMENTAL PROCEDURES
Nf2, p53, and Ink4a/Arf Conditional and Ink4a
Functional Knockout Mice
Nf2, p53, and Ink4a/Arf conditional and Ink4a functional knockout mice (Ink4a*)
have been described earlier (Giovannini et al., 2000; Marino et al., 2000; Krim-
penfort et al., 2001). All animal experiments performed in this manuscript have
been approved by our local animal experimental committee (DEC NKI). (For
details on genotyping see the Supplemental Experimental Procedures.)
Cancer Cell
A Somatic Sporadic Murine Mesothelioma ModelGeneration and Purification of Adeno-Cre Virus
The Adeno-Cre virus was constructed and propagated as described (Anton
and Graham, 1995). (For details see Supplemental Experimental Procedures.)
Recombination of the Mesothelial Cell Linings In Vivo
Rosa26R reporter mice (Soriano, 1999) or WT FVB/N mice were injected intra-
thoracically with 1 3 109 pfu of Adeno-Cre or Adeno-LacZ virus to test for the
efficiency of infection and Cre-mediated recombination of R26R in mesothelial
cells in vivo. After 7 days, mice were sacrificed and organs were processed for
b-galactosidase staining (Akagi et al., 1997). Tissues were paraffin embedded,
sectioned, and counterstained with neutral red.
Intrathoracic Injections of Adeno-Cre Virus
Nf2, p53, Ink4a/Arf conditional, and Ink4a* knockout mice were crossed to
generate different sets of compound CKO mice. As a control, we used FVB/N
mice. The experimental groups were injected IT with 2 to 5 3 108 Adeno-
Cre virus particles. In short, we filled insulin injection needles with 50 ml virus
suspension (2–53 108 pfu/50 ml) and put them on a heat sheet. We then anes-
thesized the mice with either isoflurane, or if no isoflurane anesthesia equip-
ment was available, mice were temporarily sedated by i.p. injections with Ke-
tamine:Sedacine:NaCl (2:1:17) mixture, 100 ml per 10 gmouse. When sedated,
mice were fixed on their back with thumb and pointing finger behind head
(pointing toward left side), so that the chest is in a fixed position. Injection
site was cleaned with alcohol (70%), and carefully, 50 ml of virus suspension
was injected in between ribs inside the chest (needle penetrates chest wall
from 2 to 3 mm). There was a low morbidity associated with IT injection (<2%).
IHC Analysis of the Tumors
The injectedmice weremonitored biweekly for the development of tumors and
general health status. Mice were sacrificed when signs of discomfort became
evident. Tissues from the site of Adeno-Cre injection were collected for path-
ological examination, and part of the tumors was stored at80C. The forma-
lin fixed material was sectioned, H&E stained, and analyzed microscopically.
(For a detailed description, see Supplemental Experimental Procedures.)
Southern Blot Analysis for Cre-Mediated Loss
or Loss of Heterozygosity for Nf2, p53, and Ink4a/Arf
Tumor DNA was isolated by proteinase K treatment in lysis buffer and
extracted once with buffered phenol:chloroform:isoamylalcohol (24:24:2)
and once with chloroform and precipitated with ethanol:water (2:1) (Laird
et al., 1991). Nf2 LOH analysis was performed by Southern blotting of
BamHI/XbaI digested DNA and hybridization to the 221 bp PCR probe-B (Gio-
vannini et al., 2000). For p53, we used BglII-digested DNA hybridized to the
Trp53 50 XbaI probe which is a 700 nt genomic XbaI fragment subcloned in
pBSK and labeled by PCR (Jonkers et al., 2001; Vooijs et al., 2001). For the
Ink4a probe, we cut probe B that is identical to the 1.3 kb BamHI probe
described by Serrano et al. in two parts by using the restriction enzyme XbaI
(Serrano et al., 1996). From the two resulting fragments, we hybridyzed the
500 bp fragment on Southern blots of PsiI digested DNA.
p16Ink4a Expression Study
p16Ink4a expression was studied in representative tumors from all experimental
groups to analyze a possible correlation of Ink4a loss with invasive tumor
growth behavior. Therefore, we stained several tumor sections with an
p16Ink4a antibody (Sc1207, clone M-156, Santa Cruz) as performed for other
antibodies in the section above. p16Ink4a staining was scored as either positive
nuclear staining or cytoplasmic staining or completely negative.
In Vivo Imaging of Murine MM Development
in Nf2F/F;p53 F/F(;Ink4a*/*) Mice
Nf2F/F;p53F/F(;Ink4a*/*) mice were intercrossed with LucR mice to generate
LucR;Nf2F/F;p53F/F(;Ink4a*/*) mice. After IT injection of Adeno-Cre, the mice
were imaged at fixed 1 week time intervals on the Xenogen IVIS 100 Imaging
System (Xenogen Corporation, Alameda, California) optimized for in vivo
(whole, living animals) imaging. Photon emission was used as a measure of
tumor load. Mice were sacrificed according to the same criteria used for
Nf2F/F;p53F/F(;Ink4a*/*) mice.SUPPLEMENTAL DATA
The Supplemental Data include two supplemental tables and Supplemental
Experimental Procedures and can be found with this article online at http://
www.cancercell.org/cgi/content/full/13/3/261/DC1/.
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